Replies to post #40878 on Biotech Values

[DewDiligence]

>it sucked but i got into the deal because it also came with 50 percent warrant coverage<

Similarly in this case, there’s no reason why anyone will pay $0.30 for a share on the open market when they can pay $0.30 for a share and half a warrant by buying via the offering. The market price must therefore drop to well below 0.30 for it to make any sense.

The most favored nation feature of the prior financing will cost ADH a little, but this is a small matter in the overall scheme of things. The main issue is that the latest deal is tantamount to a pre-packaged bankruptcy recapitalization as far as the existing shareholders are concerned.

[mskatiescarletohara]

ADH---

Happy New Year to you too Dr. Bio.

sometimes you need to bite the bullet if you believe in the technology

I think the tech has become a pipe dream now that GSK has walked away from both of ADH's candidates.

Still holding to see if the CEO will PR any "pump" to unload shares in the latest deal.

I'm surprised the stock is still above .30.

katie....

[krenjp]

I got caught by surprise with Conjuchem's move as well and I don't like the long extended silence of the new CEO.
However, as you say, the technology looks interesting. It has been suggested that they might clash with AMLN over the patent for Exendin which I assume is true but haven't been able to confirm. Any idea?